title: Molecular subtyping of invasive bladder cancer: time to divide and rule?
abstract: Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic characteristics. In this issue of Cancer Cell, Choi and colleagues report three molecular subtypes of MIBC with the potential to guide prognosis, patient stratification, and treatment.
authors: Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
authors: Carolyn D
authors: CD
authors: Hurst
authors: Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK. Electronic address: m.a.knowles@leeds.ac.uk.
authors: Margaret A
authors: MA
authors: Knowles
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000473:pathology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D019042:Muscle Neoplasms / Q000473:pathology*; D009154:Mutation / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53